Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris: an exploratory study - PubMed (original) (raw)

Clinical Trial

Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris: an exploratory study

Edgar A Mueller et al. Curr Med Res Opin. 2011 Apr.

Abstract

Objective: Lactoferrin, an innate defense iron-binding protein, possesses antimicrobial and anti-inflammatory activities. Beneficial systemic effects on inflammatory diseases have been proposed. The aim of the present study was to explore the efficacy and tolerability of oral bovine lactoferrin supplementation in subjects with mild to moderate facial acne vulgaris.

Methods: In this open-label, single-arm study, 43 adolescents and young adults were enrolled to take a chewable tablet formulation of bovine lactoferrin twice daily for 8 weeks. The primary efficacy endpoint was the improvement in acne lesion counts compared with baseline. Tolerability was evaluated on the basis of adverse event frequencies.

Results: Thirty-nine subjects, aged 17.5 ± 3.8 years, completed the study per protocol. At the end of the study (week 8), a mean reduction in inflammatory lesion count of 20.2% (-2.2 ± 7.0, p = 0.054), in non-inflammatory lesion count of 23.5% (-6.2 ± 9.8, p < 0.001), and in total lesion count of 22.5% (-8.4 ± 13.1, p < 0.001) was observed as compared with baseline. At study conclusion, 76.9% (30 of 39) of subjects showed a reduction in total lesion count. The results for inflammatory acne lesions were variable over the study course. None of the subjects experienced a lactoferrin-related adverse event during the trial.

Conclusion: Despite the limitations of an uncontrolled, open-label study, the results from this study indicate that lactoferrin in mild to moderate acne vulgaris is well tolerated and may lead to an overall improvement in acne lesion counts in the majority of affected adolescents and young adults when administered as a dietary supplement on a twice daily regimen. Further randomized, placebo-controlled trials of longer duration appear warranted.

PubMed Disclaimer

Cited by

Acne Vulgaris and Intake of Selected Dietary Nutrients-A Summary of Information.
Podgórska A, Puścion-Jakubik A, Markiewicz-Żukowska R, Gromkowska-Kępka KJ, Socha K. Podgórska A, et al. Healthcare (Basel). 2021 Jun 3;9(6):668. doi: 10.3390/healthcare9060668. Healthcare (Basel). 2021. PMID: 34205209 Free PMC article. Review.
Longitudinal Correlations between Molecular Compositions of Stratum Corneum and Breast Milk Factors during Infancy: A Prospective Birth Cohort Study.
Fukuda R, Pak K, Kiuchi M, Hirata N, Mochimaru N, Tanaka R, Mitsui M, Ohya Y, Yoshida K. Fukuda R, et al. Nutrients. 2024 Jun 16;16(12):1897. doi: 10.3390/nu16121897. Nutrients. 2024. PMID: 38931252 Free PMC article.
Milk Proteins-Their Biological Activities and Use in Cosmetics and Dermatology.
Kazimierska K, Kalinowska-Lis U. Kazimierska K, et al. Molecules. 2021 May 28;26(11):3253. doi: 10.3390/molecules26113253. Molecules. 2021. PMID: 34071375 Free PMC article. Review.
Effects of Lactoferrin on Subjective Skin Conditions in Winter: A Preliminary, Randomized, Double-Blinded, Placebo-Controlled Trial.
Oda H, Miyakawa M, Mizuki M, Misawa Y, Tsukahara T, Tanaka M, Yamauchi K, Abe F, Nomiyama T. Oda H, et al. Clin Cosmet Investig Dermatol. 2019 Dec 2;12:875-880. doi: 10.2147/CCID.S228153. eCollection 2019. Clin Cosmet Investig Dermatol. 2019. PMID: 31819585 Free PMC article.
VEN-120, a Recombinant Human Lactoferrin, Promotes a Regulatory T Cell [Treg] Phenotype and Drives Resolution of Inflammation in Distinct Murine Models of Inflammatory Bowel Disease.
MacManus CF, Collins CB, Nguyen TT, Alfano RW, Jedlicka P, de Zoeten EF. MacManus CF, et al. J Crohns Colitis. 2017 Sep 1;11(9):1101-1112. doi: 10.1093/ecco-jcc/jjx056. J Crohns Colitis. 2017. PMID: 28472424 Free PMC article.

Efficacy and tolerability of oral lactoferrin supplementation in mild to moderate acne vulgaris: an exploratory study - PubMed (original) (raw)